Explore more publications!
Africa News Guide
Got News to Share?

Africa News Guide: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa News Guide.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 8, 2025

Refined Energy Corp. Receives Formal Drill Program Proposal for Dufferin Project Drill Program
December 8, 2025

Refined Energy Corp. Receives Formal Drill Program Proposal for Dufferin Project Drill Program

Indeterminate GlobeNewswire
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
December 8, 2025

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs

Indeterminate GlobeNewswire
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
December 8, 2025

Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies

Indeterminate GlobeNewswire
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
December 8, 2025

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Indeterminate GlobeNewswire
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 8, 2025

Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Indeterminate GlobeNewswire
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
December 8, 2025

Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting

Indeterminate GlobeNewswire
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
December 8, 2025

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Indeterminate GlobeNewswire
Redevances OR annonce le renouvellement de son offre publique de rachat dans le cours normal des activités
December 8, 2025

Redevances OR annonce le renouvellement de son offre publique de rachat dans le cours normal des activités

Indeterminate GlobeNewswire
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
December 8, 2025

Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD

Indeterminate GlobeNewswire
OR Royalties Announces Renewal of Normal Course Issuer Bid
December 8, 2025

OR Royalties Announces Renewal of Normal Course Issuer Bid

Indeterminate GlobeNewswire
Wesdome's Surface Exploration Program at Kiena Confirms High-Grade Growth Potential
December 8, 2025

Wesdome's Surface Exploration Program at Kiena Confirms High-Grade Growth Potential

Indeterminate GlobeNewswire
Fortuna Expands Southern Arc Mineralization with Drill Intercept of 1.7 g/t Au over 29.6 meters and a further 2.0 g/t Au over 20.0 meters from DSDD574 at the Diamba Sud Gold Project, Senegal
December 8, 2025

Fortuna Expands Southern Arc Mineralization with Drill Intercept of 1.7 g/t Au over 29.6 meters and a further 2.0 g/t Au over 20.0 meters from DSDD574 at the Diamba Sud Gold Project, Senegal

Indeterminate GlobeNewswire
FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL
December 8, 2025

FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL

Indeterminate GlobeNewswire
EpiEndo Pharmaceutical's ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients
December 8, 2025

EpiEndo Pharmaceutical's ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients

Indeterminate GlobeNewswire
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
December 8, 2025

ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

Indeterminate GlobeNewswire
ASH 2025 : Cellectis présente son plan de développement pour renforcer les taux de réponse élevés obtenus avec éti-cel dans le LNH en rechute ou réfractaire
December 8, 2025

ASH 2025 : Cellectis présente son plan de développement pour renforcer les taux de réponse élevés obtenus avec éti-cel dans le LNH en rechute ou réfractaire

Indeterminate GlobeNewswire
Miltenyi Biomedicine stellt die Primäranalyse der zulassungsrelevanten DALY-2-EU-Studie zur Zweitlinientherapie des rezidivierten/refraktären großzelligen B-Zell-Lymphoms auf der 67. Jahrestagung der American Society of Hematology (ASH) vor
December 8, 2025

Miltenyi Biomedicine stellt die Primäranalyse der zulassungsrelevanten DALY-2-EU-Studie zur Zweitlinientherapie des rezidivierten/refraktären großzelligen B-Zell-Lymphoms auf der 67. Jahrestagung der American Society of Hematology (ASH) vor

Indeterminate GlobeNewswire
Miltenyi Biomedicine presenta el análisis primario del ensayo pivotal DALY 2-EU para el linfoma de células B grandes en recaída/refractario de segunda línea en la 67.ª Reunión Anual de la American Society of Hematology (ASH)
December 8, 2025

Miltenyi Biomedicine presenta el análisis primario del ensayo pivotal DALY 2-EU para el linfoma de células B grandes en recaída/refractario de segunda línea en la 67.ª Reunión Anual de la American Society of Hematology (ASH)

Indeterminate GlobeNewswire
À l’occasion de la 67e réunion annuelle de l’American Society of Hematology (ASH), Miltenyi Biomedicine présente l’analyse primaire de l’essai pivot DALY 2-EU pour le traitement de seconde ligne du lymphome à grandes cellules B en rechute ou réfractair…
December 8, 2025

À l’occasion de la 67e réunion annuelle de l’American Society of Hematology (ASH), Miltenyi Biomedicine présente l’analyse primaire de l’essai pivot DALY 2-EU pour le traitement de seconde ligne du lymphome à grandes cellules B en rechute ou réfractair…

Indeterminate GlobeNewswire
Miltenyi Biomedicine מציגה ניתוח ראשוני של ניסוי DALY 2-EU מרכזי לטיפול בהישנות/עמידות לטיפול קו שני של לימפומה של תאי B גדולים בכנס השנתי ה-67 של האגודה האמריקנית להמטולוגיה (ASH…
December 8, 2025

Miltenyi Biomedicine מציגה ניתוח ראשוני של ניסוי DALY 2-EU מרכזי לטיפול בהישנות/עמידות לטיפול קו שני של לימפומה של תאי B גדולים בכנס השנתי ה-67 של האגודה האמריקנית להמטולוגיה (ASH…

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions